Although EVI1 is overexpressed in a variety of cancers and is associated with therapy resistance and poor clinical outcome, the exact oncogenic mechanism of action downstream of EVI1 overexpression is still the subject of extensive investigation. This evidence concerns the gene MECOM and cancer.